June 9, 2025 06:48 AM EDTUpdated 08:52 AM

Sanofi leans into 'first-mover advantage' by shipping Beyfortus early, as RSV antibody market set to heat up

Ayisha Sharma

News Reporter

Sanofi on Monday said it plans to deliver its AstraZeneca-partnered RSV product Beyfortus “well ahead” of the disease season that starts in November to meet …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Sanofi leans into 'first-mover advantage' by shipping Beyfortus early, as RSV antibody market set to heat up

Ayisha Sharma

News Reporter

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Updated: Omada Health rose 21% in its public market debut

Metsera shares early data on anti-obesity amylin candidate

At a crossroads, biotechs are passing on reverse mergers in 2025

MIT scientists’ AI model one-ups AlphaFold 3, takes on ‘fundamental issue’ in drug R&D

Is there still hope for Summit's cancer drug buried in the data?

McKesson leads the charge in revolutionizing precision oncology in community practices

Sanofi leans in­to 'first-mover ad­van­tage' by ship­ping Bey­for­tus ear­ly, as RSV an­ti­body mar­ket set to heat up

News Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Sanofi leans into 'first-mover advantage' by shipping Beyfortus early, as RSV antibody market set to heat up